

Comparative Medicine: Bridging Human and Animal Health

Anil K. Verma*

Department of Veterinary Pathobiology, Eastern Plains University, India

Editorial

Received: 02-Sep-2025, Manuscript No. jvs-25-177935; **Editor assigned:** 04-Sep-2025, Pre-QC No. jvs-25-177935 (PQ); **Reviewed:** 13-Sep-2025, QC No. jvs-25-177935; **Revised:** 20-Sep-2025, Manuscript No. jvs-25-177935 (R); **Published:** 30-Sep-2025, DOI: 10.4172/2320-0189.9.001

*For Correspondence

Anil K. Verma, Department of Veterinary Pathobiology, Eastern Plains University, India

E-mail: anil.verma@epu-vet.edu.in

Citation: Anil K. Verma, Comparative Medicine: Bridging Human and Animal Health. RRJ Hosp Clin Pharm. 2025.9.001.

Copyright: © 2025 Anil K. Verma, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Comparative medicine is an interdisciplinary field that studies similarities and differences in diseases across species, particularly humans and animals. By integrating knowledge from veterinary medicine, human medicine, biology, and public health, comparative medicine provides a holistic approach to understanding disease mechanisms, prevention, and treatment. The field plays a crucial role in advancing biomedical research, improving clinical outcomes, and addressing global health challenges, especially those involving zoonotic diseases that can spread between animals and humans [1].

Discussion

At the core of comparative medicine is the concept that many biological processes and disease pathways are conserved across species. Animals, therefore, serve as valuable models for studying human diseases such as cancer, cardiovascular disorders, diabetes, and infectious diseases. For example, rodents are commonly used to investigate genetic and molecular mechanisms, while larger animals like dogs and pigs provide insights into complex physiological systems that closely resemble those of humans. These models help researchers develop and test new drugs, vaccines, and medical devices before they are applied in human medicine [2,3].

Comparative medicine is also central to the "One Health" approach, which recognizes the interconnectedness of human, animal, and environmental health. Emerging infectious diseases such as COVID-19, avian influenza, and Ebola highlight the importance of monitoring animal populations to detect and control potential threats early. Veterinarians, physicians, and researchers collaborate to track disease transmission, understand pathogen evolution, and design ef-

fective prevention strategies [4,5].

In addition to research, comparative medicine contributes to clinical practice. Findings from veterinary medicine can inform human treatments and vice versa. For instance, advances in cancer therapies, imaging techniques, and surgical procedures often move between human and animal medicine, benefiting both. Ethical considerations are also a significant aspect of the field, emphasizing responsible animal use, welfare standards, and the development of alternative research methods when possible.

Conclusion

Comparative medicine serves as a vital bridge between human and animal health, fostering collaboration across scientific and medical disciplines. By leveraging shared biological principles, the field accelerates medical innovation, enhances disease prevention, and supports global health security. As health challenges become increasingly complex and interconnected, comparative medicine will continue to be essential in promoting a comprehensive and sustainable approach to health for humans, animals, and the environment alike.

References

1. Bilen O, Ballantyne CM (2016) Bempedoic Acid (ETC-1002) An Investigational Inhibitor of ATP Citrate Lyase. *Curr Atheroscler Rep* 18: 61.
2. Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH (2019) Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases. *Cardiol Rev* 27: 49-56.
3. Benoit Viollet, Bruno Guigas, Nieves Sanz Garcia, Jocelyne Leclerc, Marc Foretz, et al. (2012) Cellular and molecular mechanisms of Bempedoic Acid. An overview, *Clinical Science (London)* 122: 253- 270.
4. Phan BA, Dayspring TD, Toth PP (2012) Ezetimibe therapy: mechanism of action and clinical update. *Vasc Health Risk Manag* 8:415-27.
5. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, et al. (2005) A review of its metabolism, pharmacokinetics and drug interactions. *Clin Pharmacokinet* 44: 467-94.